Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.
Out-of-pocket costs may affect more than patients’ wallets, raising anticipated pain and discouraging some from scheduling care, according to a new study out of Carnegie Mellon University.